You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奇正藏藥(002287.SZ):第三季度預虧3.13億元-3.62億元
格隆匯 10-14 16:47

格隆匯10月14日丨奇正藏藥(002287.SZ)披露2021年前三季度業績預吿,預計2021年1-9月實現歸屬於上市公司股東的淨利潤6.26億元-6.75億元,同比增長93.00%-108.00%;預計2021年7-9月實現歸屬於上市公司股東的淨利潤為虧損3.13億元-3.62億元,上年同期為盈利1.04億元。

公司2021年度前三季度業績較上年同期增加的主要原因為:百洋醫藥(301015.SZ)上市後,公司參與設立的併購基金西藏羣英投資中心(有限合夥)(簡稱“羣英投資”)以公開市場的價格確認公允價值變動損益增加收益,公司對此投資按照權益法進行核算,按照協議約定增加公司2021年前三季度淨利潤約25,699.13萬元,該事項屬於非經常性損益。

公司2021年第三季度公司業績虧損的主要原因為:百洋醫藥第三季度股價走低,羣英投資確認的公允價值變動收益降低,致使公司權益法核算下對此投資的投資收益減少,剔除羣英投資影響因素,公司第三季度扣非淨利潤為盈利。由於羣英投資公允價值變動損益受百洋醫藥二級市場股價波動影響較大,間接影響公司投資收益,可能會導致公司業績存在一定的波動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account